736 results on '"Sverzellati, N."'
Search Results
2. COVID-19 pneumonia imaging follow-up: when and how? A proposition from ESTI and ESR
- Author
-
Martini, K., Larici, A. R., Revel, M. P., Ghaye, B., Sverzellati, N., Parkar, A. P., Snoeckx, A., Screaton, N., Biederer, J., Prosch, H., Silva, M., Brady, A., Gleeson, F., and Frauenfelder, T.
- Published
- 2022
- Full Text
- View/download PDF
3. Effet du nintedanib chez des patients présentant une fibrose pulmonaire idiopathique et un emphysème de différentes étendues en tomodensitométrie haute résolution (TDM-HR)
- Author
-
Cottin, V., primary, Jacob, J., additional, Sverzellati, N., additional, Richeldi, L., additional, Bendstrup, E., additional, Stowasser, S., additional, Lievens, D., additional, Stansen, W., additional, and Wells, A.U., additional
- Published
- 2024
- Full Text
- View/download PDF
4. 5P Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC
- Author
-
Mazzaschi, G., primary, Barbieri, M., additional, Monica, G., additional, Pluchino, M., additional, Lorusso, B., additional, D'Agnelli, S., additional, Verzè, M., additional, Minari, R., additional, Perrone, F., additional, Bordi, P., additional, Leonetti, A., additional, Quaini, F., additional, Sverzellati, N., additional, and Tiseo, M., additional
- Published
- 2023
- Full Text
- View/download PDF
5. LUNG DUAL ENERGY CT: IMPACT OF DIFFERENT TECHNOLOGICAL APPROACHES ON QUANTITATIVE ANALYSIS
- Author
-
Ortenzia, O., primary, Maddalo, M., additional, Ghetti, C., additional, Bertolini, M., additional, Sceni, G., additional, Sverzellati, N., additional, and Silva, M., additional
- Published
- 2023
- Full Text
- View/download PDF
6. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy
- Author
-
Pastorino, U., Silva, M., Sestini, S., Sabia, F., Boeri, M., Cantarutti, A., Sverzellati, N., Sozzi, G., Corrao, G., and Marchianò, A.
- Published
- 2019
- Full Text
- View/download PDF
7. Clinical standards for diagnosis, treatment and prevention of post-COVID-19 lung disease
- Author
-
Visca, D., primary, Centis, R., additional, Pontali, E., additional, Zampogna, E., additional, Russell, A.-M., additional, Migliori, G. B., additional, Andrejak, C., additional, Aro, M., additional, Bayram, H., additional, Berkani, K., additional, Bruchfeld, J., additional, Chakaya, J. M., additional, Chorostowska-Wynimko, J., additional, Crestani, B., additional, Dalcolmo, M. P., additional, D’Ambrosio, L., additional, Dinh-Xuan, A-T., additional, Duong-Quy, S., additional, Fernandes, C., additional, García-García, J.-M., additional, de Melo Kawassaki, A, additional, Carrozzi, L., additional, Martinez-Garcia, M. A., additional, Martins, P. Carreiro, additional, Mirsaeidi, M., additional, Mohammad, Y., additional, Naidoo, R. N., additional, Neuparth, N., additional, Sese, L., additional, Silva, D. R., additional, Solovic, I., additional, Sooronbaev, T. M., additional, Spanevello, A., additional, Sverzellati, N., additional, Tanno, L., additional, Tiberi, S., additional, Vasankari, T., additional, Vasarmidi, E., additional, Vitacca, M., additional, and Annesi-Maesano, I., additional
- Published
- 2023
- Full Text
- View/download PDF
8. Effect of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis and Differing Extents of Emphysema on HRCT
- Author
-
Cottin, V., primary, Jacob, J., additional, Sverzellati, N., additional, Richeldi, L., additional, Bendstrup, E., additional, Stowasser, S., additional, Lievens, D., additional, Stansen, W., additional, and Wells, A.U., additional
- Published
- 2023
- Full Text
- View/download PDF
9. Associations Between Semi-quantitative HRCT Features and Outcomes in Patients With IPF: Data From the INPULSIS Trials
- Author
-
Jacob, J., primary, Wells, A.U., additional, Sverzellati, N., additional, Richeldi, L., additional, Bendstrup, E., additional, Stowasser, S., additional, Lievens, D., additional, Stansen, W., additional, and Cottin, V., additional
- Published
- 2023
- Full Text
- View/download PDF
10. Baseline computed tomography screening and blood microRNA predict lung cancer risk and define adequate intervals in the BioMILD trial
- Author
-
Pastorino U., Boeri M., Sestini S., Sabia F., Milanese G., Silva M., Suatoni P., Verri C., Cantarutti A., Sverzellati N., Corrao G., Marchiano A., Sozzi G., Pastorino, U, Boeri, M, Sestini, S, Sabia, F, Milanese, G, Silva, M, Suatoni, P, Verri, C, Cantarutti, A, Sverzellati, N, Corrao, G, Marchiano, A, and Sozzi, G
- Subjects
Lung Neoplasms ,microRNA ,risk profile ,Hematology ,MicroRNAs ,Oncology ,Risk Factors ,lung cancer screening ,Humans ,Mass Screening ,Prospective Studies ,low-dose computed tomography ,Tomography, X-Ray Computed ,Early Detection of Cancer - Abstract
Background: Large randomized trials have demonstrated that lung cancer (LC) screening with low-dose computed tomography (LDCT) reduces LC mortality in heavy smokers. We previously showed in the MILD screening trial that the combination of a prespecified circulating microRNA (miRNA) signature classifier (MSC) and LDCT improves the accuracy of LDCT alone. The primary aim of the prospective BioMILD study was to assess the additional value of the blood MSC assay at the time of baseline LDCT with the goal of personalizing LC screening intervals. Patients and methods: The study enrolled 4119 volunteers from January 2013 to March 2016, with a median follow-up of 5.3 years. Baseline LDCT and miRNAs stratified participants into four groups: CT−/MSC− (n = 2664; 64.7%); CT−/MSC+ (n = 800; 19.4%); CT+/MSC− (n = 446; 10.8%); and CT+/MSC+ (n = 209; 5.1%). As per the protocol, those in the CT−/MSC− and CT−/MSC+ groups were allocated to LDCT repeat at 3-year and 1-year intervals; CT+ participants were allocated for 1-year or earlier intervals on the basis of LDCT features independent of MSC results. Results: CT+ participants had a 15.8-fold higher 4-year LC incidence than CT− participants (95% confidence interval 10.34-24.05), and MSC+ participants had a 2.0-fold higher 4-year LC incidence than MSC− participants (95% confidence interval 1.40-2.90); there was no evidence that the MSC effect differed between CT+ and CT− participants. LC incidence at 4 years was 0.8% in CT−/MSC−, 1.1% in CT−/MSC+, 10.8% in CT+/MSC−, and 20.1% in CT+/MSC+ participants. LC mortality rates at 5 years in the four risk groups were 0.5 in CT−/MSC−, 1.5 in CT−/MSC+, 4.2 in CT+/MSC−, and 10.1 in CT+/MSC+. Conclusion: The combined use of LDCT and blood miRNAs at baseline predicts individual LC incidence and mortality, with a major effect of MSC for LDCT-positive individuals. These findings may have important implications in personalizing screening intervals.
- Published
- 2022
11. Lung cancer screening with low-dose CT in Europe: strength and weakness of diverse independent screening trials
- Author
-
Silva, M., Pastorino, U., and Sverzellati, N.
- Published
- 2017
- Full Text
- View/download PDF
12. Structured reporting of chest CT in COVID-19 pneumonia: a consensus proposal
- Author
-
Neri, E., Coppola, F., Larici, A. R., Sverzellati, N., Mazzei, M. A., Sacco, P., Dalpiaz, G., Feragalli, B., Miele, V., and Grassi, R.
- Published
- 2020
- Full Text
- View/download PDF
13. Baseline computed tomography screening and blood microRNA predict lung cancer risk and define adequate intervals in the BioMILD trial
- Author
-
Pastorino, U, Boeri, M, Sestini, S, Sabia, F, Milanese, G, Silva, M, Suatoni, P, Verri, C, Cantarutti, A, Sverzellati, N, Corrao, G, Marchiano, A, Sozzi, G, Pastorino U., Boeri M., Sestini S., Sabia F., Milanese G., Silva M., Suatoni P., Verri C., Cantarutti A., Sverzellati N., Corrao G., Marchiano A., Sozzi G., Pastorino, U, Boeri, M, Sestini, S, Sabia, F, Milanese, G, Silva, M, Suatoni, P, Verri, C, Cantarutti, A, Sverzellati, N, Corrao, G, Marchiano, A, Sozzi, G, Pastorino U., Boeri M., Sestini S., Sabia F., Milanese G., Silva M., Suatoni P., Verri C., Cantarutti A., Sverzellati N., Corrao G., Marchiano A., and Sozzi G.
- Abstract
Background: Large randomized trials have demonstrated that lung cancer (LC) screening with low-dose computed tomography (LDCT) reduces LC mortality in heavy smokers. We previously showed in the MILD screening trial that the combination of a prespecified circulating microRNA (miRNA) signature classifier (MSC) and LDCT improves the accuracy of LDCT alone. The primary aim of the prospective BioMILD study was to assess the additional value of the blood MSC assay at the time of baseline LDCT with the goal of personalizing LC screening intervals. Patients and methods: The study enrolled 4119 volunteers from January 2013 to March 2016, with a median follow-up of 5.3 years. Baseline LDCT and miRNAs stratified participants into four groups: CT−/MSC− (n = 2664; 64.7%); CT−/MSC+ (n = 800; 19.4%); CT+/MSC− (n = 446; 10.8%); and CT+/MSC+ (n = 209; 5.1%). As per the protocol, those in the CT−/MSC− and CT−/MSC+ groups were allocated to LDCT repeat at 3-year and 1-year intervals; CT+ participants were allocated for 1-year or earlier intervals on the basis of LDCT features independent of MSC results. Results: CT+ participants had a 15.8-fold higher 4-year LC incidence than CT− participants (95% confidence interval 10.34-24.05), and MSC+ participants had a 2.0-fold higher 4-year LC incidence than MSC− participants (95% confidence interval 1.40-2.90); there was no evidence that the MSC effect differed between CT+ and CT− participants. LC incidence at 4 years was 0.8% in CT−/MSC−, 1.1% in CT−/MSC+, 10.8% in CT+/MSC−, and 20.1% in CT+/MSC+ participants. LC mortality rates at 5 years in the four risk groups were 0.5 in CT−/MSC−, 1.5 in CT−/MSC+, 4.2 in CT+/MSC−, and 10.1 in CT+/MSC+. Conclusion: The combined use of LDCT and blood miRNAs at baseline predicts individual LC incidence and mortality, with a major effect of MSC for LDCT-positive individuals. These findings may have important implications in personalizing screening intervals.
- Published
- 2022
14. CO-10.1 - LUNG DUAL ENERGY CT: IMPACT OF DIFFERENT TECHNOLOGICAL APPROACHES ON QUANTITATIVE ANALYSIS
- Author
-
Ortenzia, O., Maddalo, M., Ghetti, C., Bertolini, M., Sceni, G., Sverzellati, N., and Silva, M.
- Published
- 2023
- Full Text
- View/download PDF
15. Prior CT Improves Deep Learning for Malignancy Risk Estimation of Screening-detected Pulmonary Nodules.
- Author
-
Venkadesh, K.V., Aleef, T.A., Scholten, E.T., Saghir, Z., Silva, M., Sverzellati, N., Pastorino, U., Ginneken, B. van, Prokop, M., Jacobs, C., Venkadesh, K.V., Aleef, T.A., Scholten, E.T., Saghir, Z., Silva, M., Sverzellati, N., Pastorino, U., Ginneken, B. van, Prokop, M., and Jacobs, C.
- Abstract
01 augustus 2023, Contains fulltext : 296016.pdf (Publisher’s version ) (Closed access), Background Prior chest CT provides valuable temporal information (eg, changes in nodule size or appearance) to accurately estimate malignancy risk. Purpose To develop a deep learning (DL) algorithm that uses a current and prior low-dose CT examination to estimate 3-year malignancy risk of pulmonary nodules. Materials and Methods In this retrospective study, the algorithm was trained using National Lung Screening Trial data (collected from 2002 to 2004), wherein patients were imaged at most 2 years apart, and evaluated with two external test sets from the Danish Lung Cancer Screening Trial (DLCST) and the Multicentric Italian Lung Detection Trial (MILD), collected in 2004-2010 and 2005-2014, respectively. Performance was evaluated using area under the receiver operating characteristic curve (AUC) on cancer-enriched subsets with size-matched benign nodules imaged 1 and 2 years apart from DLCST and MILD, respectively. The algorithm was compared with a validated DL algorithm that only processed a single CT examination and the Pan-Canadian Early Lung Cancer Detection Study (PanCan) model. Results The training set included 10 508 nodules (422 malignant) in 4902 trial participants (mean age, 64 years ± 5 [SD]; 2778 men). The size-matched external test sets included 129 nodules (43 malignant) and 126 nodules (42 malignant). The algorithm achieved AUCs of 0.91 (95% CI: 0.85, 0.97) and 0.94 (95% CI: 0.89, 0.98). It significantly outperformed the DL algorithm that only processed a single CT examination (AUC, 0.85 [95% CI: 0.78, 0.92; P = .002]; and AUC, 0.89 [95% CI: 0.84, 0.95; P = .01]) and the PanCan model (AUC, 0.64 [95% CI: 0.53, 0.74; P < .001]; and AUC, 0.63 [95% CI: 0.52, 0.74; P < .001]). Conclusion A DL algorithm using current and prior low-dose CT examinations was more effective at estimating 3-year malignancy risk of pulmonary nodules than established models that only use a single CT examination. Clinical trial registration nos. NCT00047385, NCT00496977, NCT0283780
- Published
- 2023
16. Effect of elexacaftor–tezacaftor–ivacaftor modulator on lung structure in cystic fibrosis
- Author
-
Fainardi, V., Skenderaj, K., Ciuni, A., Esposito, S., Sverzellati, N., and Pisi, G.
- Published
- 2023
- Full Text
- View/download PDF
17. Are interstitial lung abnormalities associated with COPD? A nested case–control study
- Author
-
Bozzetti F, Paladini I, Rabaiotti E, Franceschini A, Alfieri V, Chetta A, Crisafulli E, Silva M, Pastorino U, and Sverzellati N
- Subjects
interstitial lung abnormality ,chronic obstructive lung disease ,usual interstitial pneumonia ,airspace enlargement with fibrosis ,Diseases of the respiratory system ,RC705-779 - Abstract
Francesca Bozzetti,1 Ilaria Paladini,1 Enrico Rabaiotti,2 Alessandro Franceschini,1 Veronica Alfieri,3 Alfredo Chetta,3 Ernesto Crisafulli,3 Mario Silva,2 Ugo Pastorino,4 Nicola Sverzellati11Section of Radiology, Department of Surgical Sciences, University of Parma, 2Department of Radiology, Academic Hospital of Parma, 3Respiratory Disease and Lung Function Unit, Department of Clinical and Experimental Medicine, University of Parma, Parma, 4Division of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ItalyPurpose: In this study, we tested the association between COPD and interstitial lung abnormality (ILA), notably in relation to the presence of computed tomography (CT) signs of lung fibrosis.Patients and methods: COPD cases were selected from participants undergoing lung cancer screening (Multicentric Italian Lung Detection trial) for airflow obstruction (n=311/2,303, 13.5%) and 146 consecutive patients with clinical COPD. In all, 457 COPD cases were selected and classified according to the stages of Global Initiative for Chronic Obstructive Lung Disease. A nested matching (case:control =1:2) according to age, sex, and smoking history was operated between each COPD case and two control subjects from Multicentric Italian Lung Detection trial without airflow obstruction. Low-dose CT scans of COPD cases and controls were reviewed for the presence of ILA, which were classified into definite or indeterminate according to the presence of signs of lung fibrosis.Results: The frequency of definite ILA was similar between COPD cases and controls (P=0.2), independent of the presence of signs of lung fibrosis (P=0.07). Combined definite and indeterminate ILA was homogeneously distributed across Global Initiative for Chronic Obstructive Lung Disease stages (P=0.6). Definite ILA was directly associated with current smoker status (odds ratio [OR] 4.05, 95% confidence interval [CI]: 2.2–7.4) and increasing pack-years (OR 1.01, 95% CI: 1–1.02). Subjects with any fibrotic ILA were more likely to be older (OR 1.17, 95% CI: 1.10–1.25) and male (OR 8.58, 95% CI: 1.58–68.9).Conclusion: There was no association between COPD and definite ILA. However, low-dose CT signs of lung fibrosis were also observed in COPD, and their clinical relevance is yet to be determined.Keywords: interstitial lung abnormality, chronic obstructive lung disease, usual interstitial pneumonia, airspace enlargement with fibrosis
- Published
- 2016
18. Left ventricular structure and remodeling in patients with COPD
- Author
-
Pelà G, Li Calzi M, Pinelli S, Andreoli R, Sverzellati N, Bertorelli G, Goldoni M, and Chetta A
- Subjects
COPD ,Doppler tissue echocardiography ,left ventricular remodeling ,emphysema score ,right ventricular function ,left ventricular function ,Diseases of the respiratory system ,RC705-779 - Abstract
Giovanna Pelà,1 Mauro Li Calzi,1 Silvana Pinelli,1 Roberta Andreoli,1 Nicola Sverzellati,2 Giuseppina Bertorelli,1 Matteo Goldoni,1 Alfredo Chetta11Department of Clinical and Experimental Medicine, 2Department of Surgery, University Medical School, University Hospital Parma, Parma, ItalyBackground: Data on cardiac alterations such as left ventricular (LV) hypertrophy, diastolic dysfunction, and lower stroke volume in patients with COPD are discordant. In this study, we investigated whether early structural and functional cardiac changes occur in patients with COPD devoid of manifest cardiovascular disease, and we assessed their associations with clinical and functional features.Methods: Forty-nine patients with COPD belonging to all Global Initiative for Chronic Obstructive Lung Disease (GOLD) classes were enrolled and compared with 36 controls. All subjects underwent clinical history assessment, lung function testing, blood pressure measurement, electrocardiography, and conventional and Doppler tissue echocardiography. Patients were also subjected to computed tomography to quantify emphysema score.Results: Patients with COPD had lower LV cavity associated with a marked increase in relative wall thickness (RWT), suggesting concentric remodeling without significant changes in LV mass. RWT was significantly associated with ratio of the forced expiratory volume in 1 second to the forced vital capacity and emphysema score and was the only cardiac parameter that – after multivariate analysis – significantly correlated with COPD conditions in all individuals. Receiver operating characteristic curve analysis showed that RWT (with a cutoff point of 0.42) predicted the severity of COPD with 83% specificity and 56% sensitivity (area under the curve =0.69, 95% confidence interval =0.59–0.81). Patients with COPD showed right ventricular to be functional but no structural changes.Conclusion: Patients with COPD without evident cardiovascular disease exhibit significant changes in LV geometry, resulting in concentric remodeling. In all individuals, RWT was significantly and independently related to COPD. However, its prognostic role should be determined in future studies.Keywords: COPD, Doppler tissue echocardiography, left ventricular remodeling, emphysema score, right ventricular function, left ventricular function
- Published
- 2016
19. 238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors
- Author
-
Mazzaschi, G., primary, Tamarozzi, P., additional, Lorusso, B., additional, Verzè, M., additional, Pluchino, M., additional, Trentini, F., additional, Dalla Valle, B., additional, Minari, R., additional, Perrone, F., additional, Bordi, P., additional, Leonetti, A., additional, Moron Dalla Tor, L., additional, Leo, L., additional, Milanese, G., additional, Balbi, M., additional, Buti, S., additional, Roti, G., additional, Quaini, F., additional, Sverzellati, N., additional, and Tiseo, M., additional
- Published
- 2022
- Full Text
- View/download PDF
20. COVID-19 pneumonia imaging follow-up: when and how? A proposition from ESTI and ESR
- Author
-
Martini, K, Larici, A R, Revel, M P, Ghaye, B, Sverzellati, N, Parkar, A P, Snoeckx, A, Screaton, N, Biederer, J, Prosch, H, Silva, M, Brady, A, Gleeson, F, Frauenfelder, T, European Society of Thoracic Imaging (ESTI), the European Society of Radiology (ESR), University of Zurich, European Society of Thoracic Imaging (ESTI), European Society of Radiology (ESR), UCL - SSS/IREC/IMAG - Pôle d'imagerie médicale, UCL - (SLuc) Centre du cancer, and UCL - (SLuc) Service de radiologie
- Subjects
medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Acute infection ,610 Medicine & health ,Multidetector computed tomography ,Medical imaging ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,General Medicine / COVID ,Tomography ,Lung ,Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA ,Neuroradiology ,Computer. Automation ,medicine.diagnostic_test ,business.industry ,10042 Clinic for Diagnostic and Interventional Radiology ,Follow-up ,COVID-19 ,Interventional radiology ,General Medicine ,Pneumonia ,medicine.disease ,X-Ray Computed ,medicine.anatomical_structure ,Radiology Nuclear Medicine and imaging ,Chest ,Diagnostic imaging ,Organizing pneumonia ,Radiology ,Human medicine ,business ,Tomography, X-Ray Computed - Abstract
Abstract This document from the European Society of Thoracic Imaging (ESTI) and the European Society of Radiology (ESR) discusses the role of imaging in the long-term follow-up of COVID-19 patients, to define which patients may benefit from imaging, and what imaging modalities and protocols should be used. Insights into imaging features encountered on computed tomography (CT) scans and potential pitfalls are discussed and possible areas for future review and research are also included. Key Points • Post-COVID-19 pneumonia changes are mainly consistent with prior organizing pneumonia and are likely to disappear within 12 months of recovery from the acute infection in the majority of patients. • At present, with the longest series of follow-up examinations reported not exceeding 12 months, the development of persistent or progressive fibrosis in at least some individuals cannot yet be excluded. • Residual ground glass opacification may be associated with persisting bronchial dilatation and distortion, and might be termed “fibrotic-like changes” probably consistent with prior organizing pneumonia.
- Published
- 2021
21. 1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC
- Author
-
Mazzaschi, G., primary, Moron Dalla Tor, L., additional, Balbi, M., additional, Milanese, G., additional, Tognazzi, D., additional, Lorusso, B., additional, Trentini, F., additional, Di Rienzo, G., additional, Verzè, M., additional, Pluchino, M., additional, Minari, R., additional, Leo, L., additional, Gnetti, L., additional, Bordi, P., additional, Leonetti, A., additional, Ampollini, L., additional, Roti, G., additional, Quaini, F., additional, Sverzellati, N., additional, and Tiseo, M., additional
- Published
- 2022
- Full Text
- View/download PDF
22. P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer
- Author
-
Mazzaschi, G., primary, Moron Dalla Tor, L., additional, Milanese, G., additional, Balbi, M., additional, Tognazzi, D., additional, Lorusso, B., additional, Verzè, M., additional, Pluchino, M., additional, Minari, R., additional, Leo, L., additional, Ledda, R.E., additional, Bordi, P., additional, Leonetti, A., additional, Buti, S., additional, Roti, G., additional, Quaini, F., additional, Sverzellati, N., additional, and Tiseo, M., additional
- Published
- 2022
- Full Text
- View/download PDF
23. The hidden interplay between sex and COVID-19 mortality: the role of cardiovascular calcification
- Author
-
Cereda, A, Toselli, M, Palmisano, A, Vignale, D, Leone, R, Nicoletti, V, Gnasso, C, Mangieri, A, Khokhar, A, Campo, G, Scoccia, A, Bertini, M, Loffi, M, Sergio, P, Andreini, D, Pontone, G, Iannopollo, G, Nannini, T, Ippolito, D, Bellani, G, Patelli, G, Besana, F, Vignali, L, Sverzellati, N, Iannaccone, M, Vaudano, P, Sangiorgi, G, Turchio, P, Monello, A, Tumminello, G, Maggioni, A, Rapezzi, C, Colombo, A, Giannini, F, Esposito, A, Cereda A., Toselli M., Palmisano A., Vignale D., Leone R., Nicoletti V., Gnasso C., Mangieri A., Khokhar A., Campo G., Scoccia A., Bertini M., Loffi M., Sergio P., Andreini D., Pontone G., Iannopollo G., Nannini T., Ippolito D., Bellani G., Patelli G., Besana F., Vignali L., Sverzellati N., Iannaccone M., Vaudano P. G., Sangiorgi G. M., Turchio P., Monello A., Tumminello G., Maggioni A. P., Rapezzi C., Colombo A., Giannini F., Esposito A., Cereda, A, Toselli, M, Palmisano, A, Vignale, D, Leone, R, Nicoletti, V, Gnasso, C, Mangieri, A, Khokhar, A, Campo, G, Scoccia, A, Bertini, M, Loffi, M, Sergio, P, Andreini, D, Pontone, G, Iannopollo, G, Nannini, T, Ippolito, D, Bellani, G, Patelli, G, Besana, F, Vignali, L, Sverzellati, N, Iannaccone, M, Vaudano, P, Sangiorgi, G, Turchio, P, Monello, A, Tumminello, G, Maggioni, A, Rapezzi, C, Colombo, A, Giannini, F, Esposito, A, Cereda A., Toselli M., Palmisano A., Vignale D., Leone R., Nicoletti V., Gnasso C., Mangieri A., Khokhar A., Campo G., Scoccia A., Bertini M., Loffi M., Sergio P., Andreini D., Pontone G., Iannopollo G., Nannini T., Ippolito D., Bellani G., Patelli G., Besana F., Vignali L., Sverzellati N., Iannaccone M., Vaudano P. G., Sangiorgi G. M., Turchio P., Monello A., Tumminello G., Maggioni A. P., Rapezzi C., Colombo A., Giannini F., and Esposito A.
- Abstract
Recent clinical and demographical studies on COVID-19 patients have demonstrated that men experience worse outcomes than women. However, in most cases, the data were not stratified according to gender, limiting the understanding of the real impact of gender on outcomes. This study aimed to evaluate the disaggregated in-hospital outcomes and explore the possible interactions between gender and cardiovascular calcifications. Data was derived from the sCORE-COVID-19 registry, an Italian multicentre registry that enrolled COVID-19 patients who had undergone a chest computer tomography scan on admission. A total of 1683 hospitalized patients (mean age 67±14 years) were included. Men had a higher prevalence of cardiovascular comorbidities, a higher pneumonia extension, more coronary calcifications (63% vs.50.9%, p<0.001), and a higher coronary calcium score (391±847 vs. 171±479 mm3, p<0.001). Men experienced a significantly higher mortality rate (24.4% vs. 17%, p=0.001), but the death event tended to occur earlier in women (15±7 vs. 8±7 days, p= 0.07). Non-survivors had a higher coronary, thoracic aorta, and aortic valve calcium score. Female sex, a known independent predictor of a favorable outcome in SARS-CoV2 infection, was not protective in women with a coronary calcification volume greater than 100 mm3. There were significant differences in cardiovascular comorbidities and vascular calcifications between men and women with SARS-CoV2 pneumonia. The differences in outcomes can be at least partially explained by the different cardiovascular profiles. However, women with poor outcomes had the same coronary calcific burden as men. The presumed favorable female sex bias in COVID-19 must therefore be reviewed in the context of comorbidities, especially cardiovascular ones.
- Published
- 2021
24. CarDiac magnEtic Resonance for prophylactic Implantable-cardioVerter defibrillAtor ThErapy in Non-Ischaemic dilated CardioMyopathy: an international Registry
- Author
-
Guaricci, A, Masci, P, Muscogiuri, G, Guglielmo, M, Baggiano, A, Fusini, L, Lorenzoni, V, Martini, C, Andreini, D, Pavon, A, Aquaro, G, Barison, A, Todiere, G, Rabbat, M, Tat, E, Raineri, C, Valentini, A, Varga-Szemes, A, Schoepf, U, De Cecco, C, Bogaert, J, Dobrovie, M, Symons, R, Focardi, M, Gismondi, A, Lozano-Torres, J, Rodriguez-Palomares, J, Lanzillo, C, Di Roma, M, Moro, C, Di Giovine, G, Margonato, D, De Lazzari, M, Perazzolo Marra, M, Nese, A, Casavecchia, G, Gravina, M, Marzo, F, Carigi, S, Pica, S, Lombardi, M, Censi, S, Squeri, A, Palumbo, A, Gaibazzi, N, Camastra, G, Sbarbati, S, Pedrotti, P, Masi, A, Carrabba, N, Pradella, S, Timpani, M, Cicala, G, Presicci, C, Puglisi, S, Sverzellati, N, Santobuono, V, Pepi, M, Schwitter, J, Pontone, G, Guaricci AI, Masci PG, Muscogiuri G, Guglielmo M, Baggiano A, Fusini L, Lorenzoni V, Martini C, Andreini D, Pavon AG, Aquaro GD, Barison A, Todiere G, Rabbat MG, Tat E, Raineri C, Valentini A, Varga-Szemes A, Schoepf UJ, De Cecco CN, Bogaert J, Dobrovie M, Symons R, Focardi M, Gismondi A, Lozano-Torres J, Rodriguez-Palomares JF, Lanzillo C, Di Roma M, Moro C, Di Giovine G, Margonato D, De Lazzari M, Perazzolo Marra M, Nese A, Casavecchia G, Gravina M, Marzo F, Carigi S, Pica S, Lombardi M, Censi S, Squeri A, Palumbo A, Gaibazzi N, Camastra G, Sbarbati S, Pedrotti P, Masi A, Carrabba N, Pradella S, Timpani M, Cicala G, Presicci C, Puglisi S, Sverzellati N, Santobuono VE, Pepi M, Schwitter J, Pontone G, Guaricci, A, Masci, P, Muscogiuri, G, Guglielmo, M, Baggiano, A, Fusini, L, Lorenzoni, V, Martini, C, Andreini, D, Pavon, A, Aquaro, G, Barison, A, Todiere, G, Rabbat, M, Tat, E, Raineri, C, Valentini, A, Varga-Szemes, A, Schoepf, U, De Cecco, C, Bogaert, J, Dobrovie, M, Symons, R, Focardi, M, Gismondi, A, Lozano-Torres, J, Rodriguez-Palomares, J, Lanzillo, C, Di Roma, M, Moro, C, Di Giovine, G, Margonato, D, De Lazzari, M, Perazzolo Marra, M, Nese, A, Casavecchia, G, Gravina, M, Marzo, F, Carigi, S, Pica, S, Lombardi, M, Censi, S, Squeri, A, Palumbo, A, Gaibazzi, N, Camastra, G, Sbarbati, S, Pedrotti, P, Masi, A, Carrabba, N, Pradella, S, Timpani, M, Cicala, G, Presicci, C, Puglisi, S, Sverzellati, N, Santobuono, V, Pepi, M, Schwitter, J, Pontone, G, Guaricci AI, Masci PG, Muscogiuri G, Guglielmo M, Baggiano A, Fusini L, Lorenzoni V, Martini C, Andreini D, Pavon AG, Aquaro GD, Barison A, Todiere G, Rabbat MG, Tat E, Raineri C, Valentini A, Varga-Szemes A, Schoepf UJ, De Cecco CN, Bogaert J, Dobrovie M, Symons R, Focardi M, Gismondi A, Lozano-Torres J, Rodriguez-Palomares JF, Lanzillo C, Di Roma M, Moro C, Di Giovine G, Margonato D, De Lazzari M, Perazzolo Marra M, Nese A, Casavecchia G, Gravina M, Marzo F, Carigi S, Pica S, Lombardi M, Censi S, Squeri A, Palumbo A, Gaibazzi N, Camastra G, Sbarbati S, Pedrotti P, Masi A, Carrabba N, Pradella S, Timpani M, Cicala G, Presicci C, Puglisi S, Sverzellati N, Santobuono VE, Pepi M, Schwitter J, and Pontone G
- Abstract
Aims: The aim of this registry was to evaluate the additional prognostic value of a composite cardiac magnetic resonance (CMR)-based risk score over standard-of-care (SOC) evaluation in a large cohort of consecutive unselected non-ischaemic cardiomyopathy (NICM) patients. Methods and results: In the DERIVATE registry (www.clinicaltrials.gov/registration: RCT#NCT03352648), 1000 (derivation cohort) and 508 (validation cohort) NICM patients with chronic heart failure (HF) and left ventricular ejection fraction [removed]3 segments with midwall fibrosis on late gadolinium enhancement (LGE) were the only independent predictors of all-cause mortality (HR: 1.036, 95% CI: 1.0117-1.056, P < 0.001 and HR: 2.077, 95% CI: 1.211-3.562, P = 0.008, respectively). For MAACE, the independent predictors were male gender, left ventricular end-diastolic volume index by CMR (CMR-LVEDVi), and >3 segments with midwall fibrosis on LGE (HR: 2.131, 95% CI: 1.231-3.690, P = 0.007; HR: 3.161, 95% CI: 1.750-5.709, P < 0.001; and HR: 1.693, 95% CI: 1.084-2.644, P = 0.021, respectively). A composite clinical and CMR-based risk score provided a net reclassification improvement of 63.7% (P < 0.001) for MAACE occurrence when added to the model based on SOC evaluation. These findings were confirmed in the validation cohort. Conclusion: In a large multicentre, multivendor cohort registry reflecting daily clinical practice in NICM work-up, a composite clinical and CMR-based risk score provides incremental prognostic value beyond SOC evaluation, which may have impact on the indication of implantable cardioverter-defibrillator implantation.
- Published
- 2021
25. Frequency and characterization of ancillary chest CT findings in COVID-19 pneumonia
- Author
-
Silva, M, Ledda, R, Schiebler, M, Balbi, M, Sironi, S, Milone, F, Affanni, P, Milanese, G, Sverzellati, N, Silva M., Ledda R. E., Schiebler M., Balbi M., Sironi S., Milone F., Affanni P., Milanese G., Sverzellati N., Silva, M, Ledda, R, Schiebler, M, Balbi, M, Sironi, S, Milone, F, Affanni, P, Milanese, G, Sverzellati, N, Silva M., Ledda R. E., Schiebler M., Balbi M., Sironi S., Milone F., Affanni P., Milanese G., and Sverzellati N.
- Abstract
Objectives: Ground-glass opacity and consolidation are recognized typical features of Coronavirus disease-19 (COVID-19) pneumonia on Chest CT, yet ancillary findings have not been fully described. We aimed to describe ancillary findings of COVID-19 pneumonia on CT, to define their prevalence, and investigate their association with clinical data. Methods: We retrospectively reviewed our CT chest cases with coupled reverse transcriptase polymerase chain reaction (rt-PCR). Patients with negative rt-PCR or without admission chest CT were excluded. Ancillary findings included: vessel enlargement, subpleural curvilinear lines, dependent subpleural atelectasis, centrilobular solid nodules, pleural and/or pericardial effusions, enlarged mediastinal lymph nodes. Continuous data were expressed as median and 95% confidence interval (95% CI) and tested by Mann–Whitney U test. Results: Ancillary findings were represented by 106/252 (42.1%, 36.1 to 48.2) vessel enlargement, 50/252 (19.8%, 15.4 to 25.2) subpleural curvilinear lines, 26/252 (10.1%, 7.1 to 14.7) dependent subpleural atelectasis, 15/252 (5.9%, 3.6 to 9.6) pleural effusion, 15/252 (5.9%, 3.6 to 9.6) mediastinal lymph nodes enlargement, 13/252 (5.2%, 3 to 8.6) centrilobular solid nodules, and 6/252 (2.4%, 1.1 to 5.1) pericardial effusion. Air space disease was more extensive in patients with vessel enlargement or centrilobular solid nodules (p < 0.001). Vessel enlargement was associated with longer history of fever (p = 0.035) and lower admission oxygen saturation (p = 0.014); dependent subpleural atelectasis with lower oxygen saturation (p < 0.001) and higher respiratory rate (p < 0.001); mediastinal lymph nodes with shorter history of cough (p = 0.046); centrilobular solid nodules with lower prevalence of cough (p = 0.023), lower oxygen saturation (p < 0.001), and higher respiratory rate (p = 0.032), and pericardial effusion with shorter history of cough (p = 0.015). Ancillary findings associated with lon
- Published
- 2021
26. P131 Clinical impact of Aspergillus fumigatus in children with cystic fibrosis
- Author
-
Fainardi, V., primary, De Olmi, M., additional, Sodini, C., additional, Skenderaj, K., additional, Ciuni, A., additional, Zani, E. Mariotti, additional, Stabile, M.B., additional, Spaggiari, C., additional, Longo, F., additional, Sverzellati, N., additional, Esposito, S., additional, and Pisi, G., additional
- Published
- 2022
- Full Text
- View/download PDF
27. COVID-19 pneumonia imaging follow-up: when and how? A proposition from ESTI and ESR.
- Author
-
UCL - SSS/IREC/IMAG - Pôle d'imagerie médicale, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service de radiologie, Martini, K, Larici, A R, Revel, M P, Ghaye, B, Sverzellati, N, Parkar, A P, Snoeckx, A, Screaton, N, Biederer, J, Prosch, H, Silva, M, Brady, A, Gleeson, F, Frauenfelder, T, European Society of Thoracic Imaging (ESTI), the European Society of Radiology (ESR), UCL - SSS/IREC/IMAG - Pôle d'imagerie médicale, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service de radiologie, Martini, K, Larici, A R, Revel, M P, Ghaye, B, Sverzellati, N, Parkar, A P, Snoeckx, A, Screaton, N, Biederer, J, Prosch, H, Silva, M, Brady, A, Gleeson, F, Frauenfelder, T, and European Society of Thoracic Imaging (ESTI), the European Society of Radiology (ESR)
- Abstract
This document from the European Society of Thoracic Imaging (ESTI) and the European Society of Radiology (ESR) discusses the role of imaging in the long-term follow-up of COVID-19 patients, to define which patients may benefit from imaging, and what imaging modalities and protocols should be used. Insights into imaging features encountered on computed tomography (CT) scans and potential pitfalls are discussed and possible areas for future review and research are also included. KEY POINTS: • Post-COVID-19 pneumonia changes are mainly consistent with prior organizing pneumonia and are likely to disappear within 12 months of recovery from the acute infection in the majority of patients. • At present, with the longest series of follow-up examinations reported not exceeding 12 months, the development of persistent or progressive fibrosis in at least some individuals cannot yet be excluded. • Residual ground glass opacification may be associated with persisting bronchial dilatation and distortion, and might be termed "fibrotic-like changes" probably consistent with prior organizing pneumonia.
- Published
- 2022
28. Scan-based competing death risk model for re-evaluating lung cancer computed tomography screening eligibility
- Author
-
Schreuder, A., Jacobs, C., Lessmann, N., Broeders, M.J.M., Silva, M., Isgum, I., Jong, P.A. de, Heuvel, M.M. van den, Sverzellati, N., Prokop, M., Pastorino, U., Schaefer-Prokop, C.M., Ginneken, B. van, Schreuder, A., Jacobs, C., Lessmann, N., Broeders, M.J.M., Silva, M., Isgum, I., Jong, P.A. de, Heuvel, M.M. van den, Sverzellati, N., Prokop, M., Pastorino, U., Schaefer-Prokop, C.M., and Ginneken, B. van
- Abstract
Item does not contain fulltext, BACKGROUND: A baseline computed tomography (CT) scan for lung cancer (LC) screening may reveal information indicating that certain LC screening participants can be screened less, and instead require dedicated early cardiac and respiratory clinical input. We aimed to develop and validate competing death (CD) risk models using CT information to identify participants with a low LC risk and a high CD risk. METHODS: Participant demographics and quantitative CT measures of LC, cardiovascular disease and chronic obstructive pulmonary disease were considered for deriving a logistic regression model for predicting 5-year CD risk using a sample from the National Lung Screening Trial (n=15 000). Multicentric Italian Lung Detection data were used to perform external validation (n=2287). RESULTS: Our final CD model outperformed an external pre-scan model (CD Risk Assessment Tool) in both the derivation (area under the curve (AUC) 0.744 (95% CI 0.727-0.761) and 0.677 (95% CI 0.658-0.695), respectively) and validation cohorts (AUC 0.744 (95% CI 0.652-0.835) and 0.725 (95% CI 0.633-0.816), respectively). By also taking LC incidence risk into consideration, we suggested a risk threshold where a subgroup (6258/23 096 (27%)) was identified with a number needed to screen to detect one LC of 216 (versus 23 in the remainder of the cohort) and ratio of 5.41 CDs per LC case (versus 0.88). The respective values in the validation cohort subgroup (774/2287 (34%)) were 129 (versus 29) and 1.67 (versus 0.43). CONCLUSIONS: Evaluating both LC and CD risks post-scan may improve the efficiency of LC screening and facilitate the initiation of multidisciplinary trajectories among certain participants.
- Published
- 2022
29. Ablative Radiotherapy (ART) for Locally Advanced Pancreatic Cancer (LAPC): Toward a New Paradigm?
- Author
-
Simoni, N., Rossi, G., Cellini, Francesco, Vitolo, V., Orlandi, E., Valentini, Vincenzo, Mazzarotto, R., Sverzellati, N., D'Abbiero, N., Cellini F. (ORCID:0000-0002-2145-2300), Valentini V. (ORCID:0000-0003-4637-6487), Simoni, N., Rossi, G., Cellini, Francesco, Vitolo, V., Orlandi, E., Valentini, Vincenzo, Mazzarotto, R., Sverzellati, N., D'Abbiero, N., Cellini F. (ORCID:0000-0002-2145-2300), and Valentini V. (ORCID:0000-0003-4637-6487)
- Abstract
Locally advanced pancreatic cancer (LAPC) represents a major urgency in oncology. Due to the massive involvement of the peripancreatic vessels, a curative-intent surgery is generally precluded. Historically, LAPC has been an indication for palliative systemic therapy. In recent years, with the introduction of intensive multi-agent chemotherapy regimens and aggressive surgical approaches, the survival of LAPC patients has significantly improved. In this complex and rapidly evolving scenario, the role of radiotherapy is still debated. The use of standard-dose conventional fractionated radiotherapy in LAPC has led to unsatisfactory oncological outcomes. However, technological advances in radiation therapy over recent years have definitively changed this paradigm. The use of ablative doses of radiotherapy, in association with image-guidance, respiratory organ-motion management, and adaptive protocols, has led to unprecedented results in terms of local control and survival. In this overview, principles, clinical applications, and current pitfalls of ablative radiotherapy (ART) as an emerging treatment option for LAPC are discussed.
- Published
- 2022
30. COVID-19 pneumonia imaging follow-up: when and how? A proposition from ESTI and ESR
- Author
-
Martini, K; https://orcid.org/0000-0002-2638-6832, Larici, A R, Revel, M P, Ghaye, B, Sverzellati, N, Parkar, A P, Snoeckx, A, Screaton, N, Biederer, J, Prosch, H, Silva, M, Brady, A, Gleeson, F, Frauenfelder, T, Martini, K; https://orcid.org/0000-0002-2638-6832, Larici, A R, Revel, M P, Ghaye, B, Sverzellati, N, Parkar, A P, Snoeckx, A, Screaton, N, Biederer, J, Prosch, H, Silva, M, Brady, A, Gleeson, F, and Frauenfelder, T
- Abstract
This document from the European Society of Thoracic Imaging (ESTI) and the European Society of Radiology (ESR) discusses the role of imaging in the long-term follow-up of COVID-19 patients, to define which patients may benefit from imaging, and what imaging modalities and protocols should be used. Insights into imaging features encountered on computed tomography (CT) scans and potential pitfalls are discussed and possible areas for future review and research are also included. KEY POINTS: • Post-COVID-19 pneumonia changes are mainly consistent with prior organizing pneumonia and are likely to disappear within 12 months of recovery from the acute infection in the majority of patients. • At present, with the longest series of follow-up examinations reported not exceeding 12 months, the development of persistent or progressive fibrosis in at least some individuals cannot yet be excluded. • Residual ground glass opacification may be associated with persisting bronchial dilatation and distortion, and might be termed "fibrotic-like changes" probably consistent with prior organizing pneumonia. Keywords: COVID-19; Diagnostic imaging; Follow-up; Lung; Multidetector computed tomography
- Published
- 2022
31. 165P Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens
- Author
-
Mazzaschi, G., primary, Verzè, M., additional, Tognazzi, D., additional, Lorusso, B., additional, Minari, R., additional, Pluchino, M., additional, Trentini, F., additional, Manini, M., additional, Bordi, P., additional, Leonetti, A., additional, Perrone, F., additional, Corianò, M., additional, Casali, M., additional, Toscani, I., additional, Cosenza, A., additional, Ferri, L., additional, Buti, S., additional, Sverzellati, N., additional, Quaini, F., additional, and Tiseo, M., additional
- Published
- 2022
- Full Text
- View/download PDF
32. 17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients
- Author
-
Mazzaschi, G., primary, Milanese, G., additional, Moron Dalla Tor, L., additional, Leo, L., additional, Balbi, M., additional, Trentini, F., additional, Manini, M., additional, Pavone, C., additional, Silva, M., additional, Ledda, R.E., additional, Minari, R., additional, Bordi, P., additional, Buti, S., additional, Leonetti, A., additional, Roti, G., additional, Quaini, F., additional, Sverzellati, N., additional, and Tiseo, M., additional
- Published
- 2021
- Full Text
- View/download PDF
33. Dosimetric and radiation cancer risk evaluation of high resolution thorax CT during COVID-19 outbreak
- Author
-
Ghetti, C., primary, Ortenzia, O., additional, Maddalo, M., additional, Altabella, L., additional, and Sverzellati, N., additional
- Published
- 2021
- Full Text
- View/download PDF
34. Ten-year results of the Multicentric Italian Lung Detection trial demonstrate the safety and efficacy of biennial lung cancer screening
- Author
-
Pastorino, U, Sverzellati, N, Sestini, S, Silva, M, Sabia, F, Boeri, M, Cantarutti, A, Sozzi, G, Corrao, G, Marchiano, A, Pastorino U., Sverzellati N., Sestini S., Silva M., Sabia F., Boeri M., Cantarutti A., Sozzi G., Corrao G., Marchiano A., Pastorino, U, Sverzellati, N, Sestini, S, Silva, M, Sabia, F, Boeri, M, Cantarutti, A, Sozzi, G, Corrao, G, Marchiano, A, Pastorino U., Sverzellati N., Sestini S., Silva M., Sabia F., Boeri M., Cantarutti A., Sozzi G., Corrao G., and Marchiano A.
- Abstract
Background: The Multicentric Italian Lung Detection (MILD) trial demonstrated that prolonged low-dose computed tomography (LDCT) screening could achieve a 39% reduction in lung cancer (LC) mortality. We have here evaluated the long-term results of annual vs. biennial LDCT and the impact of screening intensity on overall and LC-specific mortality at 10 years. Patients and methods: Between 2005 and 2018, the MILD trial prospectively randomised the 2376 screening arm participants to annual (n = 1190) or biennial (n = 1186) LDCT, for a median screening period of 6.2 years and 23,083 person-years of follow-up. The primary outcomes were 10-year overall and LC-specific mortality, and the secondary end-points were the frequency of advanced-stage and interval LCs. Results: The biennial LDCT arm showed a similar overall mortality (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.57–1.12) and LC-specific mortality at 10 years (HR 1.10, 95% CI 0.59–2.05), as compared with the annual LDCT arm. Biennial screening saved 44% of follow-up LDCTs in subjects with negative baseline LDCT, and 38% of LDCTs in all participants, with no increase in the occurrence of stage II-IV or interval LCs. Conclusions: The MILD trial provides original evidence that prolonged screening beyond five years with biennial LDCT can achieve an LC mortality reduction comparable to annual LDCT, in subjects with a negative baseline examination.
- Published
- 2019
35. Erratum: ERRATUM: Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: New confirmation of lung cancer screening efficacy (Ann Oncol (2019) DOI:10.1093/annonc/mdz117)
- Author
-
Pastorino U., Pastorino, U, Silva, M, Sestini, S, Sabia, F, Boeri, M, Cantarutti, A, Sverzellati, N, Sozzi, G, Corrao, G, Marchiano, A, Pastorino U., Silva M., Sestini S., Sabia F., Boeri M., Cantarutti A., Sverzellati N., Sozzi G., Corrao G., Marchiano A., Pastorino U., Pastorino, U, Silva, M, Sestini, S, Sabia, F, Boeri, M, Cantarutti, A, Sverzellati, N, Sozzi, G, Corrao, G, Marchiano, A, Pastorino U., Silva M., Sestini S., Sabia F., Boeri M., Cantarutti A., Sverzellati N., Sozzi G., Corrao G., and Marchiano A.
- Abstract
In the original article, the Figure 1 caption contained an erroneous sentence. It has now been corrected to read: ‘Cumulative overall mortality and lung cancermortality, by arm over 10 years of follow-up.’ The Publisher apologizes for the error.
- Published
- 2019
36. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy
- Author
-
Pastorino, U, Silva, M, Sestini, S, Sabia, F, Boeri, M, Cantarutti, A, Sverzellati, N, Sozzi, G, Corrao, G, Marchiano, A, Pastorino U., Silva M., Sestini S., Sabia F., Boeri M., Cantarutti A., Sverzellati N., Sozzi G., Corrao G., Marchiano A., Pastorino, U, Silva, M, Sestini, S, Sabia, F, Boeri, M, Cantarutti, A, Sverzellati, N, Sozzi, G, Corrao, G, Marchiano, A, Pastorino U., Silva M., Sestini S., Sabia F., Boeri M., Cantarutti A., Sverzellati N., Sozzi G., Corrao G., and Marchiano A.
- Abstract
Background: The National Lung Screening Trial showed that lung cancer (LC) screening by three annual rounds of low-dose computed tomography (LDCT) reduces LC mortality. We evaluated the benefit of prolonged LDCT screening beyond 5 years, and its impact on overall and LC specific mortality at 10 years. Design: The Multicentric Italian Lung Detection (MILD) trial prospectively randomized 4099 participants, to a screening arm (n = 2376), with further randomization to annual (n = 1190) or biennial (n = 1186) LDCT for a median period of 6 years, or control arm (n = 1723) without intervention. Between 2005 and 2018, 39 293 person-years of follow-up were accumulated. The primary outcomes were 10-year overall and LC specific mortality. Landmark analysis was used to test the long-term effect of LC screening, beyond 5 years by exclusion of LCs and deaths that occurred in the first 5 years. Results: The LDCT arm showed a 39% reduced risk of LC mortality at 10 years [hazard ratio (HR) 0.61; 95% confidence interval (CI) 0.39-0.95], compared with control arm, and a 20% reduction of overall mortality (HR 0.80; 95% CI 0.62-1.03). LDCT benefit improved beyond the 5th year of screening, with a 58% reduced risk of LC mortality (HR 0.42; 95% CI 0.22-0.79), and 32% reduction of overall mortality (HR 0.68; 95% CI 0.49-0.94). Conclusions: The MILD trial provides additional evidence that prolonged screening beyond 5 years can enhance the benefit of early detection and achieve a greater overall and LC mortality reduction compared with NLST trial. ClinicalTrials.gov identifier: NCT02837809.
- Published
- 2019
37. P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC
- Author
-
Mazzaschi, G., primary, Scandino, R., additional, Milanese, G., additional, Pavone, C., additional, Balbi, M., additional, Ledda, R., additional, Minari, R., additional, Trentini, F., additional, Bordi, P., additional, Buti, S., additional, Leonetti, A., additional, Quaini, F., additional, Sverzellati, N., additional, Romanel, A., additional, and Tiseo, M., additional
- Published
- 2021
- Full Text
- View/download PDF
38. 1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy
- Author
-
Mazzaschi, G., primary, Scandino, R., additional, Milanese, G., additional, Pavone, C., additional, Maurizio, B., additional, Silva, M., additional, Ledda, R., additional, Minari, R., additional, Trentini, F., additional, Buti, S., additional, Bordi, P., additional, Leonetti, A., additional, Quaini, F., additional, Sverzellati, N., additional, Romanel, A., additional, and Tiseo, M., additional
- Published
- 2021
- Full Text
- View/download PDF
39. 452P Predicting response to bevacizumab in colorectal cancer by integrating radiomics to clinical and genomic features
- Author
-
Milanese, G., primary, Maddalo, M., additional, Leo, L., additional, Lecchini, M., additional, Bottarelli, L., additional, Gnetti, L., additional, Campanini, N., additional, Pedrazzi, G., additional, Azzoni, C., additional, Bozzetti, C., additional, Zavani, A., additional, Caruana, P., additional, Silini, E.M., additional, Sverzellati, N., additional, and Negri, F., additional
- Published
- 2021
- Full Text
- View/download PDF
40. Magnetic resonance imaging in the complications of kidney transplantation
- Author
-
Onniboni, M., De Filippo, M., Averna, R., Coco, L., Zompatori, M., Sverzellati, N., and Rossi, C.
- Published
- 2013
- Full Text
- View/download PDF
41. Screening for lung cancer using low-dose spiral CT: 10 years later, state of the art
- Author
-
Zompatori, M., Mascalchi, M., Ciccarese, F., Sverzellati, N., and Pastorino, U.
- Published
- 2013
- Full Text
- View/download PDF
42. AB0578 SUBCLINICAL ENTHESITIS IN PSORIASIS patiEntS AS prediCtor OF ARTHRITIS (EPESCA STUDY): PRELIMINARY RESULTS
- Author
-
Di Donato, E., primary, Becciolini, A., additional, DI Nuzzo, S., additional, Chernyschova, N., additional, Commisso, C., additional, Lamorte, S., additional, Brusasco, M., additional, Pierobon, E., additional, Santilli, D., additional, Lucchini, G., additional, Riva, M., additional, Sverzellati, N., additional, Mozzani, F., additional, and Ariani, A., additional
- Published
- 2021
- Full Text
- View/download PDF
43. A Multidisciplinary Multicenter Study Evaluating Risk Factors, Prevalence and Characteristics of Post-COVID-19 Interstitial Lung Syndrome PCOILS
- Author
-
Tomassetti, S., primary, Oggionni, T., additional, Barisione, E., additional, Bargagli, E., additional, Bonifazi, M., additional, Confalonieri, M., additional, Caminati, A., additional, Scala, R., additional, Gasparini, S., additional, Harari, S., additional, klersy, C., additional, Meloni, F., additional, Torricella, A., additional, Aloe, T., additional, Luzzi, V., additional, Gori, L., additional, Ferraro, S., additional, Marinato, M., additional, Biadene, G., additional, Cozzi, D., additional, Cavigli, E., additional, Miele, V., additional, Piciucchi, S., additional, Sverzellati, N., additional, Puglisi, S., additional, Poletti, V., additional, and Ravaglia, C., additional
- Published
- 2021
- Full Text
- View/download PDF
44. Lung cancer screening by nodule volume in Lung-RADS v1.1: negative baseline CT yields potential for increased screening interval
- Author
-
Silva, M., Milanese, G., Sestini, S., Sabia, F., Jacobs, C., Ginneken, B. van, Prokop, M., Schaefer-Prokop, C.M., Marchiano, A., Sverzellati, N., Pastorino, U., Silva, M., Milanese, G., Sestini, S., Sabia, F., Jacobs, C., Ginneken, B. van, Prokop, M., Schaefer-Prokop, C.M., Marchiano, A., Sverzellati, N., and Pastorino, U.
- Abstract
Contains fulltext : 232913.pdf (Publisher’s version ) (Open Access), OBJECTIVES: The 2019 Lung CT Screening Reporting & Data System version 1.1 (Lung-RADS v1.1) introduced volumetric categories for nodule management. The aims of this study were to report the distribution of Lung-RADS v1.1 volumetric categories and to analyse lung cancer (LC) outcomes within 3 years for exploring personalized algorithm for lung cancer screening (LCS). METHODS: Subjects from the Multicentric Italian Lung Detection (MILD) trial were retrospectively selected by National Lung Screening Trial (NLST) criteria. Baseline characteristics included selected pre-test metrics and nodule characterization according to the volume-based categories of Lung-RADS v1.1. Nodule volume was obtained by segmentation with dedicated semi-automatic software. Primary outcome was diagnosis of LC, tested by univariate and multivariable models. Secondary outcome was stage of LC. Increased interval algorithms were simulated for testing rate of delayed diagnosis (RDD) and reduction of low-dose computed tomography (LDCT) burden. RESULTS: In 1248 NLST-eligible subjects, LC frequency was 1.2% at 1 year, 1.8% at 2 years and 2.6% at 3 years. Nodule volume in Lung-RADS v1.1 was a strong predictor of LC: positive LDCT showed an odds ratio (OR) of 75.60 at 1 year (p < 0.0001), and indeterminate LDCT showed an OR of 9.16 at 2 years (p = 0.0068) and an OR of 6.35 at 3 years (p = 0.0042). In the first 2 years after negative LDCT, 100% of resected LC was stage I. The simulations of low-frequency screening showed a RDD of 13.6-21.9% and a potential reduction of LDCT burden of 25.5-41%. CONCLUSIONS: Nodule volume by semi-automatic software allowed stratification of LC risk across Lung-RADS v1.1 categories. Personalized screening algorithm by increased interval seems feasible in 80% of NLST eligible. KEY POINTS: * Using semi-automatic segmentation of nodule volume, Lung-RADS v1.1 selected 10.8% of subjects with positive CT and 96.87 relative risk of lung cancer at 1 year, compared to negative CT. *
- Published
- 2021
45. A Low-Dose CT-Based Radiomic Model to Improve Characterization and Screening Recall Intervals of Indeterminate Prevalent Pulmonary Nodules
- Author
-
Rundo, L, Ledda, R, di Noia, C, Sala, E, Mauri, G, Milanese, G, Sverzellati, N, Apolone, G, Gilardi, M, Messa, M, Castiglioni, I, Pastorino, U, Rundo, Leonardo, Ledda, Roberta Eufrasia, di Noia, Christian, Sala, Evis, Mauri, Giancarlo, Milanese, Gianluca, Sverzellati, Nicola, Apolone, Giovanni, Gilardi, Maria Carla, Messa, Maria Cristina, Castiglioni, Isabella, Pastorino, Ugo, Rundo, L, Ledda, R, di Noia, C, Sala, E, Mauri, G, Milanese, G, Sverzellati, N, Apolone, G, Gilardi, M, Messa, M, Castiglioni, I, Pastorino, U, Rundo, Leonardo, Ledda, Roberta Eufrasia, di Noia, Christian, Sala, Evis, Mauri, Giancarlo, Milanese, Gianluca, Sverzellati, Nicola, Apolone, Giovanni, Gilardi, Maria Carla, Messa, Maria Cristina, Castiglioni, Isabella, and Pastorino, Ugo
- Abstract
Lung cancer (LC) is currently one of the main causes of cancer-related deaths worldwide. Low-dose computed tomography (LDCT) of the chest has been proven effective in secondary prevention (i.e., early detection) of LC by several trials. In this work, we investigated the potential impact of radiomics on indeterminate prevalent pulmonary nodule (PN) characterization and risk stratification in subjects undergoing LDCT-based LC screening. As a proof-of-concept for radiomic analyses, the first aim of our study was to assess whether indeterminate PNs could be automatically classified by an LDCT radiomic classifier as solid or sub-solid (first-level classification), and in particular for sub-solid lesions, as non-solid versus part-solid (second-level classification). The second aim of the study was to assess whether an LCDT radiomic classifier could automatically predict PN risk of malignancy, and thus optimize LDCT recall timing in screening programs. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), accuracy, positive predictive value, negative predictive value, sensitivity, and specificity. The experimental results showed that an LDCT radiomic machine learning classifier can achieve excellent performance for characterization of screen-detected PNs (mean AUC of 0.89 ± 0.02 and 0.80 ± 0.18 on the blinded test dataset for the first-level and second-level classifiers, respectively), providing quantitative information to support clinical management. Our study showed that a radiomic classifier could be used to optimize LDCT recall for indeterminate PNs. According to the performance of such a classifier on the blinded test dataset, within the first 6 months, 46% of the malignant PNs and 38% of the benign ones were identified, improving early detection of LC by doubling the current detection rate of malignant nodules from 23% to 46% at a low cost of false positives. In conclusion, we showed the high potential of LDCT-based r
- Published
- 2021
46. Coronary and total thoracic calcium scores predict mortality and provides pathophysiologic insights in COVID-19 patients
- Author
-
Giannini, F, Toselli, M, Palmisano, A, Cereda, A, Vignale, D, Leone, R, Nicoletti, V, Gnasso, C, Monello, A, Manfrini, M, Khokhar, A, Sticchi, A, Biagi, A, Turchio, P, Tacchetti, C, Landoni, G, Boccia, E, Campo, G, Scoccia, A, Ponticelli, F, Danzi, G, Loffi, M, Muri, M, Pontone, G, Andreini, D, Mancini, E, Casella, G, Iannopollo, G, Nannini, T, Ippolito, D, Bellani, G, Franzesi, C, Patelli, G, Besana, F, Costa, C, Vignali, L, Benatti, G, Sverzellati, N, Scarnecchia, E, Lombardo, F, Anastasio, F, Iannaccone, M, Vaudano, P, Pacielli, A, Baffoni, L, Gardi, I, Cesini, E, Sperandio, M, Micossi, C, De Carlini, C, Spreafico, C, Maggiolini, S, Bonaffini, P, Iacovoni, A, Sironi, S, Senni, M, Fominskiy, E, De Cobelli, F, Maggioni, A, Rapezzi, C, Ferrari, R, Colombo, A, Esposito, A, Giannini, Francesco, Toselli, Marco, Palmisano, Anna, Cereda, Alberto, Vignale, Davide, Leone, Riccardo, Nicoletti, Valeria, Gnasso, Chiara, Monello, Alberto, Manfrini, Marco, Khokhar, Arif, Sticchi, Alessandro, Biagi, Andrea, Turchio, Piergiorgio, Tacchetti, Carlo, Landoni, Giovanni, Boccia, Edda, Campo, Gianluca, Scoccia, Alessandra, Ponticelli, Francesco, Danzi, Gian Battista, Loffi, Marco, Muri, Margherita, Pontone, Gianluca, Andreini, Daniele, Mancini, Elisabetta Maria, Casella, Gianni, Iannopollo, Gianmarco, Nannini, Tommaso, Ippolito, Davide, Bellani, Giacomo, Franzesi, Camillo Talei, Patelli, Gianluigi, Besana, Francesca, Costa, Claudia, Vignali, Luigi, Benatti, Giorgio, Sverzellati, Nicola, Scarnecchia, Elisa, Lombardo, Francesco Paolo, Anastasio, Fabio, Iannaccone, Mario, Vaudano, Paolo Giacomo, Pacielli, Alberto, Baffoni, Lucio, Gardi, Iljia, Cesini, Elisabetta, Sperandio, Massimiliano, Micossi, Chiara, De Carlini, Caterina Chiara, Spreafico, Cristiano, Maggiolini, Stefano, Bonaffini, Pietro Andrea, Iacovoni, Attilio, Sironi, Sandro, Senni, Michele, Fominskiy, Evgeny, De Cobelli, Francesco, Maggioni, Aldo Pietro, Rapezzi, Claudio, Ferrari, Roberto, Colombo, Antonio, Esposito, Antonio, Giannini, F, Toselli, M, Palmisano, A, Cereda, A, Vignale, D, Leone, R, Nicoletti, V, Gnasso, C, Monello, A, Manfrini, M, Khokhar, A, Sticchi, A, Biagi, A, Turchio, P, Tacchetti, C, Landoni, G, Boccia, E, Campo, G, Scoccia, A, Ponticelli, F, Danzi, G, Loffi, M, Muri, M, Pontone, G, Andreini, D, Mancini, E, Casella, G, Iannopollo, G, Nannini, T, Ippolito, D, Bellani, G, Franzesi, C, Patelli, G, Besana, F, Costa, C, Vignali, L, Benatti, G, Sverzellati, N, Scarnecchia, E, Lombardo, F, Anastasio, F, Iannaccone, M, Vaudano, P, Pacielli, A, Baffoni, L, Gardi, I, Cesini, E, Sperandio, M, Micossi, C, De Carlini, C, Spreafico, C, Maggiolini, S, Bonaffini, P, Iacovoni, A, Sironi, S, Senni, M, Fominskiy, E, De Cobelli, F, Maggioni, A, Rapezzi, C, Ferrari, R, Colombo, A, Esposito, A, Giannini, Francesco, Toselli, Marco, Palmisano, Anna, Cereda, Alberto, Vignale, Davide, Leone, Riccardo, Nicoletti, Valeria, Gnasso, Chiara, Monello, Alberto, Manfrini, Marco, Khokhar, Arif, Sticchi, Alessandro, Biagi, Andrea, Turchio, Piergiorgio, Tacchetti, Carlo, Landoni, Giovanni, Boccia, Edda, Campo, Gianluca, Scoccia, Alessandra, Ponticelli, Francesco, Danzi, Gian Battista, Loffi, Marco, Muri, Margherita, Pontone, Gianluca, Andreini, Daniele, Mancini, Elisabetta Maria, Casella, Gianni, Iannopollo, Gianmarco, Nannini, Tommaso, Ippolito, Davide, Bellani, Giacomo, Franzesi, Camillo Talei, Patelli, Gianluigi, Besana, Francesca, Costa, Claudia, Vignali, Luigi, Benatti, Giorgio, Sverzellati, Nicola, Scarnecchia, Elisa, Lombardo, Francesco Paolo, Anastasio, Fabio, Iannaccone, Mario, Vaudano, Paolo Giacomo, Pacielli, Alberto, Baffoni, Lucio, Gardi, Iljia, Cesini, Elisabetta, Sperandio, Massimiliano, Micossi, Chiara, De Carlini, Caterina Chiara, Spreafico, Cristiano, Maggiolini, Stefano, Bonaffini, Pietro Andrea, Iacovoni, Attilio, Sironi, Sandro, Senni, Michele, Fominskiy, Evgeny, De Cobelli, Francesco, Maggioni, Aldo Pietro, Rapezzi, Claudio, Ferrari, Roberto, Colombo, Antonio, and Esposito, Antonio
- Abstract
Background: Coronavirus disease 2019 (COVID-19) has spread worldwide determining dramatic impacts on healthcare systems. Early identification of high-risk parameters is required in order to provide the best therapeutic approach. Coronary, thoracic aorta and aortic valve calcium can be measured from a non-gated chest computer tomography (CT) and are validated predictors of cardiovascular events and all-cause mortality. However, their prognostic role in acute systemic inflammatory diseases, such as COVID-19, has not been investigated. Objectives: The aim was to evaluate the association of coronary artery calcium and total thoracic calcium on in-hospital mortality in COVID-19 patients. Methods: 1093 consecutive patients from 16 Italian hospitals with a positive swab for COVID-19 and an admission chest CT for pneumonia severity assessment were included. At CT, coronary, aortic valve and thoracic aorta calcium were qualitatively and quantitatively evaluated separately and combined together (total thoracic calcium) by a central Core-lab blinded to patients’ outcomes. Results: Non-survivors compared to survivors had higher coronary artery [Agatston (467.76 ± 570.92 vs 206.80 ± 424.13 mm2, p < 0.001); Volume (487.79 ± 565.34 vs 207.77 ± 406.81, p < 0.001)], aortic valve [Volume (322.45 ± 390.90 vs 98.27 ± 250.74 mm2, p < 0.001; Agatston 337.38 ± 414.97 vs 111.70 ± 282.15, p < 0.001)] and thoracic aorta [Volume (3786.71 ± 4225.57 vs 1487.63 ± 2973.19 mm2, p < 0.001); Agatston (4688.82 ± 5363.72 vs 1834.90 ± 3761.25, p < 0.001)] calcium values. Coronary artery calcium (HR 1.308; 95% CI, 1.046–1.637, p = 0.019) and total thoracic calcium (HR 1.975; 95% CI, 1.200–3.251, p = 0.007) resulted to be independent predictors of in-hospital mortality. Conclusion: Coronary, aortic valve and thoracic aortic calcium assessment on admission non-gated CT permits to stratify the COVID-19 patients in-hospital mortality risk.
- Published
- 2021
47. Rheumatoid arthritis related interstitial lung disease
- Author
-
Manfredi, A, Cassone, G, Luppi, F, Atienza-Mateo, B, Cavazza, A, Sverzellati, N, González-Gay, M, Salvarani, C, Sebastiani, M, Andreina, Manfredi, Giulia, Cassone, Fabrizio, Luppi, Belen, Atienza-Mateo, Alberto, Cavazza, Nicola, Sverzellati, Miguel Angel, González-Gay, Carlo, Salvarani, Marco, Sebastiani, Manfredi, A, Cassone, G, Luppi, F, Atienza-Mateo, B, Cavazza, A, Sverzellati, N, González-Gay, M, Salvarani, C, Sebastiani, M, Andreina, Manfredi, Giulia, Cassone, Fabrizio, Luppi, Belen, Atienza-Mateo, Alberto, Cavazza, Nicola, Sverzellati, Miguel Angel, González-Gay, Carlo, Salvarani, and Marco, Sebastiani
- Abstract
INTRODUCTION: Interstitial lung disease (ILD) represents one of the most frequent extra-articular manifestations of rheumatoid arthritis (RA) with a deep impact on both quality of life and overall prognosis. A literature search was performed trough some electronic databases, including PubMed, Embase, Scopus, and Web of Science. Areas covered: Many retrospective studies investigated the possible risk factors for RA-ILD, aiming to early identify patients at risk. Among them, male sex, smoking habit, positivity of anti-citrullinated peptide antibodies have been associated to RA-ILD, such as some genetic haplotypes. Histologic and radiologic patterns detected in idiopathic interstitial pneumonias (IIP) have also been observed in RA; among them, usual interstitial pneumonia is the most frequently observed, followed by nonspecific interstitial pneumonia. Since lung involvement can represent the RA onset, an early differential diagnosis with IIP can be difficult or sometimes impossible. High resolution computed tomography represents the gold standard for ILD diagnosis, while multidisciplinary discussion should be required to assess disease staging, severity and progression. Expert opinion: Management of RA-ILD patients are challenging due to the lacking of evidence-based data regarding both assessment and treatment. Moreover, the high variability of clinical presentation and evolution makes difficult to establish the correct therapeutic strategy. Currently, multidisciplinary approach, including at least rheumatologists, pulmonologists, and radiologists, is desirable to define therapy and follow-up strategies.
- Published
- 2021
48. Interstitial lung disease in Sjögren's syndrome: a clinical review
- Author
-
Luppi, F, Sebastiani, M, Silva, M, Sverzellati, N, Cavazza, A, Salvarani, C, Manfredi, A, Luppi, Fabrizio, Sebastiani, Marco, Silva, Mario, Sverzellati, Nicola, Cavazza, Alberto, Salvarani, Carlo, Manfredi, Andreina, Luppi, F, Sebastiani, M, Silva, M, Sverzellati, N, Cavazza, A, Salvarani, C, Manfredi, A, Luppi, Fabrizio, Sebastiani, Marco, Silva, Mario, Sverzellati, Nicola, Cavazza, Alberto, Salvarani, Carlo, and Manfredi, Andreina
- Abstract
Interstitial lung disease (ILD) is considered the most frequent and serious pulmonary complication in primary Sjögren's syndrome (pSS), with the majority of the studies indicating a prevalence of about 20%, and resulting in significant morbidity and mortality. Although ILD was historically described as a late manifestation of pSS, more recently, a high variability of the time of onset of pSS-ILD has been observed and from 10 to 51% of patients can develop ILD years before the onset of pSS. Lymphocytic interstitial pneumonia is highly typical for SS, but it occurs only in a few cases, while the most common ILD pattern is nonspecific interstitial pneumonia, followed by usual interstitial pneumonia and organising pneumonia. Multidisciplinary discussion can be necessary in pSS cases with ambiguous clinical findings, when differential diagnosis with IIPs might be very difficult. Up to date, available data do not allow to establish an evidence-based treatment strategy in pSS-ILD. Glucocorticoids are empirically used, usually in association to immunosuppressive drugs, such as cyclophosphamide and mycophenolate mofetil. A better understanding of the molecular mechanisms involved in the pathogenesis of pSS should facilitate the development of new therapies. Recently, a trial showed the efficacy of the antifibrotic drug nintedanib in slowing progression of various interstitial lung diseases, including patients with connective tissue diseases. The aims of this review are to describe clinical features, imaging, pathology, together with diagnostic criteria, prognosis and management of pSS-ILD patients.
- Published
- 2021
49. Follow-up in pulmonary sarcoidosis: comparison between HRCT and pulmonary function tests
- Author
-
Gafà, G., Sverzellati, N., Bonati, E., Chetta, A., Franco, F., Rabaiotti, E., De Filippo, M., Marangio, E., Figoli, D., Meschi, T., Zompatori, M., and Rossi, C.
- Published
- 2012
- Full Text
- View/download PDF
50. 2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients
- Author
-
Mazzaschi, G., Cardinale, E., Pluchino, M., Monica, G., Lorusso, B., D'Agnelli, S., Trentini, F., Tamarozzi, P., Dalla Tor, L. Moron, Verzè, M., Minari, R., Bordi, P., Perrone, F., Leonetti, A., Gnetti, L., Roti, G., Quaini, F., Sverzellati, N., and Tiseo, M.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.